Lilly’s impact doesn’t stop with the creation of new medicines. We also work with global health systems and organizations to ensure equitable access to our medicines and address complex global health challenges, such as the COVID-19 pandemic and the growing prevalence of diabetes.
We’ve established an aggressive goal – Lilly 30x30 – to improve annual access to quality health care for 30 million people living in communities with limited resources by 2030. In 2019, our most recent data, we reached 7.2 million people. And in the past year, Lilly took several significant steps to advance toward our goal:
We began an allocation program with the Bill & Melinda Gates Foundation to supply our COVID-19 antibodies to low- and middle-income countries.
We announced a major expansion of support to organizations that donate to Life for a Child, which provides life-saving insulin to young people in need.
We committed $100 million to the AMR Action Fund, which aims to bring new antibiotics to patients to fight antimicrobial resistance.
Lilly Global Health: By the Numbers
2.4M
vials of insulin donated to Life for a Child since 2009
$90M
committed to global health efforts through 2022
30M
people our Lilly 30x30 initiative aims to help access quality health care each year by 2030
Global Health Highlights
Life for a Child: Helping Children Living with Diabetes
Lilly Cautionary Statement Regarding Forward-Looking Statements
This document contains forward-looking statements that are based on management’s current expectations, but actual results may differ materially due to various factors. The company’s operations, results, business, goals and strategy may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes or developments in laws and regulations, including health care reform.
For additional information about the factors that affect the company’s business, please see the company’s latest Forms 10-K, 10-Q, and any 8-Ks filed with the Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements except as required by applicable law.
Find more detail on Lilly’s environmental, social and governance priorities, strategies and operations.